NVGN Key Stats
PR Newswire09/03 19:48
PR Newswire08/13 08:00
PR Newswire08/12 08:13
PR Newswire07/25 07:00
PR Newswire05/27 07:00
PR Newswire05/04 18:19
|11/15/2013||Misc||AGM Event for Novogen Limited|
NVGN Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Novogen is down 14.11% over the last year vs S&P 500 Total Return up 20.89%, AstraZeneca up 51.49%, and Bristol-Myers Squibb up 20.83%.
Balance Sheet View Statement
Y-Ratings for NVGN
Portfolio Strategies Featuring NVGN
Did Novogen make it into our Portfolio Strategies?
Start your YCharts membership now to find out.
- Sector: Healthcare
- Industry: Drug Manufacturers - Major
- Company Website: http://www.novogen.com
- IR Website: http://www.novogen.com/annual-reports
- HQ Country: Australia
- HQ State/Province: N/A
- Incorporation Country: Australia
- Incorporation State/Province: N/A
- Est. Current Fiscal Quarter End: September 30, 2014
- Est. Current Fiscal Year End: June 30, 2015
- Last Fiscal Quarter End: December 31, 2013
- Last Fiscal Year End: June 30, 2013
Novogen Ltd is engaged in pharmaceutical drug development. It develops single drug capable of killing both the dominant differentiated cells in a cancer as well as the undifferentiated cancer stem cells at a therapeutic dose.
NVGN Excel Add-In Codes
- Name: =YCI("NVGN","name")
- Description: =YCI("NVGN","description")
- Sector: =YCI("NVGN","sector")
- Industry: =YCI("NVGN","industry")
- Est. Current Fiscal Year End: =YCI("NVGN","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.